

Preethi Jeyaraman<sup>1</sup>, Alka Bhasin<sup>2</sup>, Nitin Dayal<sup>3</sup>,  
Sangeeta Pathak<sup>4</sup>, Rahul Naithani<sup>1</sup>

<sup>1</sup>Division of Hematology and Bone Marrow Transplant,  
<sup>2</sup>Department of Nephrology, <sup>3</sup>Department of Pathology,  
<sup>4</sup>Department of Transfusion Medicine, Max Super-Specialty  
Hospital, New Delhi, India

**Correspondence to: Preethi Jeyaraman**  
Division of Hematology and Bone Marrow Transplant, Max  
Super-Specialty Hospital, Saket, New Delhi 110017, India  
E-mail: preethijeyaraman1@gmail.com

Received on Aug. 1, 2019; Revised on Dec. 3, 2019; Accepted on Jan. 13, 2020  
<https://doi.org/10.5045/br.2020.55.1.65>

#### Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

#### REFERENCES

- Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *J Hematol Oncol* 2016;9:51.
- Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med* 2016;375:1319-31.
- Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med* 2016;375:754-66.
- Yan X, Clemens PL, Puchalski T, et al. Target-mediated drug disposition of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitors and immunomodulatory drugs: a population pharmacokinetic analysis. *Blood* 2015;126:4222.
- Dimopoulos M, Weisel K, van de Donk NWCJ, et al. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: results from a phase II trial. *J Clin Oncol* 2018;36:2035-43.
- Quach H, White D, Spencer A, et al. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. *Cancer Chemother Pharmacol* 2017;79:1067-76.
- Ma X, Wong SW, Zhou P, et al. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. *Exp Hematol Oncol* 2018;7:27.
- Cejalvo MJ, Legarda M, Abella E, et al. Activity and safety of daratumumab monotherapy in patients with relapsed and refractory multiple myeloma requiring dialysis: preliminary results of Spanish, retrospective, multicenter trial. *Blood (ASH Annual Meeting Abstracts)* 2017;130(Suppl 1):1866.
- Rocchi S, Tacchetti P, Pantani L, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. *Haematologica* 2018;103:e277-8.
- Smyth E, Glavey S, Melotti D, et al. Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure. *Ir J Med Sci* 2019;188:1079-80.

## Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?

**TO THE EDITOR:** In a recent issue of *Blood Research*, Song and colleagues highlighted the number of patients with cerebral infarctions and either erythrocytosis or thrombocytosis in whom further investigation of a myeloproliferative neoplasm (MPN) was not sought [1]. Extrapolated globally, where the lifetime risk of stroke is approximately 25%, this seemingly small number of patients with an underlying MPN would represent a considerable proportion of worldwide stroke cases in which intervention with specific MPN-directed therapies, both established and novel, would be missed [2, 3].

This important finding raises some considerations. In addition to improved communication between hematologists and neurologists, would the authors suggest implementation and justification of an MPN-associated molecular screening programme for all patients with stroke, regardless of the presence of an erythrocytosis or thrombocytosis? Furthermore, the vast majority of MPN patients presenting with stroke have molecular evidence of the *JAK2* V617F mutation, however rare cases harboring *JAK2* exon 12, *MPL* exon 10 and *CALR* exon 9 mutations have been reported [4-6]. Would the authors therefore consider incorporating these other MPN-associated driver mutations into any molecular screening programme? As MPN-directed therapy should be regarded as an integral component of secondary stroke prevention [7], identification or exclusion of this underlying malignant cause should be a priority.

**Stephen E. Langabeer**

*Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland*

**Correspondence to: Stephen E. Langabeer**

*Cancer Molecular Diagnostics, Trinity Translational Medicine Institute, St. James's Hospital, Dublin D08 W9RT, Ireland*  
E-mail: slangabeer@stjames.ie

Received on Feb. 17, 2020; Accepted on Mar. 7, 2020  
<https://doi.org/10.5045/br.2020.55.1.67>

#### Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

#### REFERENCES

- Song IC, Choi YS, Shin JW, Song HJ, Kim J, Jo DY. Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the

revised 2016 World Health Organization diagnostic criteria. *Blood Res* 2019;54:284-5.

2. GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. *N Engl J Med* 2018;379:2429-37.
3. Economides MP, Verstovsek S, Pemmaraju N. Novel therapies in myeloproliferative neoplasms (MPN): beyond JAK inhibitors. *Curr Hematol Malig Rep* 2019;14:460-8.
4. Anderson N, Bonsell K. Ischemic stroke as the presenting symptom in a young patient with essential thrombocythemia caused by CALR gene mutation. *Neurology (AAN 67th Annual Meeting Abstracts)* 2015;84(Suppl):abst P2.253.
5. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. *Blood* 2008;112:141-9.
6. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. *Blood* 2008;111:1686-9.
7. Stefanou MI, Richter H, Härtig F, et al. Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms. *Eur J Neurol* 2019;26:903-e64.

## Response to the letter by Langabeer on “Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria”

**TO Dr. LANGABEER:** Thank you for your interests in our observations and good suggestions. Thromboembolism can precede overt presentation of a myeloproliferative neoplasm (MPN) by a few years. In this context, your suggestions on the molecular testing in stroke patients may be reasonable. Mayo Clinic has screened *JAK2V617F* in patients with 664 patients with non-splanchic thrombosis, including 136 strokes. *JAK2V617F* was found in only 6 patients, and the mutant allele burden was low in all instances (2.2–7.5%). Based on these observations, they concluded that mutation screening was not warranted as part of the hypercoagulable work-up in the absence of MPN [1]. In addition,

*JAK2V617F* seems to be found in normal population [2]. Furthermore, currently early detection of MPN driver gene mutations does not confer therapeutic implications in stroke patients with normal hematologic features, because available hematologic intervention such as cytoreductive therapy is indicated only in patients with overt thrombocytosis or erythrocytosis. Accordingly, we need to pay more attention to hematologic alterations at the time of diagnosis and regular follow-up of hematologic tests in patients with stroke rather than routine molecular screening, at least in daily clinical practice. For the selected cases of embolic stroke or cerebrovascular sinus thrombosis with otherwise undetermined source, molecular screening for MPN may be reasonable even in the absence of abnormal hematologic findings [3]. Collectively, molecular screening for MPN in stroke patients is still an open question, requiring prospective investigations and discussions.

**Ik-Chan Song**

*Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea*

**Correspondence to: Ik-Chan Song**

*Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, Chungnam National University, 266 Munhwa-ro, Daejeon 35015, Korea*  
E-mail: petrosong@naver.com

Received on Feb. 17, 2020; Accepted on Mar. 7, 2020

<https://doi.org/10.5045/br.2020.55.1.68>

### Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

### REFERENCES

1. Pardanani A, Lasho TL, Hussein K, et al. *JAK2V617F* mutation screening as part of the hypercoagulable work-up in the absence of splanchic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. *Mayo Clin Proc* 2008;83:457-9.
2. Xu X, Zhang Q, Luo J, et al. *JAK2(V617F)*: Prevalence in a large Chinese hospital population. *Blood* 2007;109:339-42.
3. Trifan G, Shafi N, Testai FD. Implications of janus kinase 2 mutation in embolic stroke of unknown source. *J Stroke Cerebrovasc Dis* 2018;27:2572-8.